Biogen easily tops Street estimates on Spinraza sales, raises forecast 24 julio, 2018 0 Biogen Inc reported far better-than-expected second quarter profit on Tuesday, driven by strong demand of its Spinraza muscle disease treatment, and the U.S. biotech company raised its full-year profit forecast. Source: Reuters FacebookTwitterLinkedIn